Angiotensin-Converting Enzyme Inhibition Partially Prevents Diabetic Organomegaly

Melkon Hajinazarian, Fernando G. Cosio, Norris Stanley Nahman, John D. Mahan, Cynthia McAllister

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The present study was conducted to evaluate whether captopril prevents the organomegaly and accumulation of matrix proteins that normally accompanies the diabetic state. The following groups of rats were studied: normal rats, normal rats treated with captopril (30 mg/kg/d orally), streptozotocin diabetic rats, and diabetic rats treated with captopril. All rats were killed at 10 weeks for histologic and morphometric evaluation of tissues. Compared with the normal rats, the diabetic rats demonstrated significant hepatomegaly, nephromegaly, and cardiomegaly, and the increase in organ size was directly related to increasing levels of protein glycosylation. The development of organomegaly was partially prevented by captopril. We determined by morphometry that the hepatomegaly seen in the diabetic rats was due to an increase in cell size and number, while the nephromegaly seen in the diabetic rats was due to an increase in tubular and glomerular cell size and is associated with glomerular hypertrophy. Captopril prevented the development of hepatic and renal cell hypertrophy and glomerular hypertrophy. These effects of captopril were not associated with detectable changes in body weight or levels of glucose, protein glycosylation, glycosuria, or renal histologic changes secondary to glycosuria. The diabetic rats demonstrated significant glomerular mesangial matrix expansion, and captopril treatment partially prevented that expansion. In conclusion, captopril prevents, in part, the development of organomegaly in diabetic rats, and this effect is due mainly to the prevention of the development of cellular hypertrophy. The present findings are most consistent with a direct effect of captopril on cell metabolism during diabetes mellitus.

Original languageEnglish (US)
Pages (from-to)105-117
Number of pages13
JournalAmerican Journal of Kidney Diseases
Volume23
Issue number1
DOIs
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

Peptidyl-Dipeptidase A
Captopril
Hypertrophy
Hepatomegaly
Glycosylation
Cell Size
Renal Glycosuria
Glycosuria
Body Weight Changes
Organ Size
Cardiomegaly
Streptozocin
Hepatocytes
Diabetes Mellitus
Cell Count
Kidney
Glucose

Keywords

  • Diabetes
  • angiotensin
  • hypertrophy
  • nephropathy
  • organomegaly

ASJC Scopus subject areas

  • Nephrology

Cite this

Angiotensin-Converting Enzyme Inhibition Partially Prevents Diabetic Organomegaly. / Hajinazarian, Melkon; Cosio, Fernando G.; Nahman, Norris Stanley; Mahan, John D.; McAllister, Cynthia.

In: American Journal of Kidney Diseases, Vol. 23, No. 1, 01.01.1994, p. 105-117.

Research output: Contribution to journalArticle

Hajinazarian, Melkon ; Cosio, Fernando G. ; Nahman, Norris Stanley ; Mahan, John D. ; McAllister, Cynthia. / Angiotensin-Converting Enzyme Inhibition Partially Prevents Diabetic Organomegaly. In: American Journal of Kidney Diseases. 1994 ; Vol. 23, No. 1. pp. 105-117.
@article{481402d694ab4bb78d33cffc36b5ef2f,
title = "Angiotensin-Converting Enzyme Inhibition Partially Prevents Diabetic Organomegaly",
abstract = "The present study was conducted to evaluate whether captopril prevents the organomegaly and accumulation of matrix proteins that normally accompanies the diabetic state. The following groups of rats were studied: normal rats, normal rats treated with captopril (30 mg/kg/d orally), streptozotocin diabetic rats, and diabetic rats treated with captopril. All rats were killed at 10 weeks for histologic and morphometric evaluation of tissues. Compared with the normal rats, the diabetic rats demonstrated significant hepatomegaly, nephromegaly, and cardiomegaly, and the increase in organ size was directly related to increasing levels of protein glycosylation. The development of organomegaly was partially prevented by captopril. We determined by morphometry that the hepatomegaly seen in the diabetic rats was due to an increase in cell size and number, while the nephromegaly seen in the diabetic rats was due to an increase in tubular and glomerular cell size and is associated with glomerular hypertrophy. Captopril prevented the development of hepatic and renal cell hypertrophy and glomerular hypertrophy. These effects of captopril were not associated with detectable changes in body weight or levels of glucose, protein glycosylation, glycosuria, or renal histologic changes secondary to glycosuria. The diabetic rats demonstrated significant glomerular mesangial matrix expansion, and captopril treatment partially prevented that expansion. In conclusion, captopril prevents, in part, the development of organomegaly in diabetic rats, and this effect is due mainly to the prevention of the development of cellular hypertrophy. The present findings are most consistent with a direct effect of captopril on cell metabolism during diabetes mellitus.",
keywords = "Diabetes, angiotensin, hypertrophy, nephropathy, organomegaly",
author = "Melkon Hajinazarian and Cosio, {Fernando G.} and Nahman, {Norris Stanley} and Mahan, {John D.} and Cynthia McAllister",
year = "1994",
month = "1",
day = "1",
doi = "10.1016/S0272-6386(12)80819-5",
language = "English (US)",
volume = "23",
pages = "105--117",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Angiotensin-Converting Enzyme Inhibition Partially Prevents Diabetic Organomegaly

AU - Hajinazarian, Melkon

AU - Cosio, Fernando G.

AU - Nahman, Norris Stanley

AU - Mahan, John D.

AU - McAllister, Cynthia

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The present study was conducted to evaluate whether captopril prevents the organomegaly and accumulation of matrix proteins that normally accompanies the diabetic state. The following groups of rats were studied: normal rats, normal rats treated with captopril (30 mg/kg/d orally), streptozotocin diabetic rats, and diabetic rats treated with captopril. All rats were killed at 10 weeks for histologic and morphometric evaluation of tissues. Compared with the normal rats, the diabetic rats demonstrated significant hepatomegaly, nephromegaly, and cardiomegaly, and the increase in organ size was directly related to increasing levels of protein glycosylation. The development of organomegaly was partially prevented by captopril. We determined by morphometry that the hepatomegaly seen in the diabetic rats was due to an increase in cell size and number, while the nephromegaly seen in the diabetic rats was due to an increase in tubular and glomerular cell size and is associated with glomerular hypertrophy. Captopril prevented the development of hepatic and renal cell hypertrophy and glomerular hypertrophy. These effects of captopril were not associated with detectable changes in body weight or levels of glucose, protein glycosylation, glycosuria, or renal histologic changes secondary to glycosuria. The diabetic rats demonstrated significant glomerular mesangial matrix expansion, and captopril treatment partially prevented that expansion. In conclusion, captopril prevents, in part, the development of organomegaly in diabetic rats, and this effect is due mainly to the prevention of the development of cellular hypertrophy. The present findings are most consistent with a direct effect of captopril on cell metabolism during diabetes mellitus.

AB - The present study was conducted to evaluate whether captopril prevents the organomegaly and accumulation of matrix proteins that normally accompanies the diabetic state. The following groups of rats were studied: normal rats, normal rats treated with captopril (30 mg/kg/d orally), streptozotocin diabetic rats, and diabetic rats treated with captopril. All rats were killed at 10 weeks for histologic and morphometric evaluation of tissues. Compared with the normal rats, the diabetic rats demonstrated significant hepatomegaly, nephromegaly, and cardiomegaly, and the increase in organ size was directly related to increasing levels of protein glycosylation. The development of organomegaly was partially prevented by captopril. We determined by morphometry that the hepatomegaly seen in the diabetic rats was due to an increase in cell size and number, while the nephromegaly seen in the diabetic rats was due to an increase in tubular and glomerular cell size and is associated with glomerular hypertrophy. Captopril prevented the development of hepatic and renal cell hypertrophy and glomerular hypertrophy. These effects of captopril were not associated with detectable changes in body weight or levels of glucose, protein glycosylation, glycosuria, or renal histologic changes secondary to glycosuria. The diabetic rats demonstrated significant glomerular mesangial matrix expansion, and captopril treatment partially prevented that expansion. In conclusion, captopril prevents, in part, the development of organomegaly in diabetic rats, and this effect is due mainly to the prevention of the development of cellular hypertrophy. The present findings are most consistent with a direct effect of captopril on cell metabolism during diabetes mellitus.

KW - Diabetes

KW - angiotensin

KW - hypertrophy

KW - nephropathy

KW - organomegaly

UR - http://www.scopus.com/inward/record.url?scp=0028044716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028044716&partnerID=8YFLogxK

U2 - 10.1016/S0272-6386(12)80819-5

DO - 10.1016/S0272-6386(12)80819-5

M3 - Article

VL - 23

SP - 105

EP - 117

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 1

ER -